Hcw Biologics Inc. · NASDAQ:HCWB
Hcw Biologics — IPO Roadshow (July 2021)
12 slides from Hcw Biologics's IPO roadshow presentation, Jul 12, 2021
Slide 1: Novel Immunotherapeutics for Cancer and Other Age-Associated Diseases
Novel Immunotherapeutics for Cancer and Other Age-Associated Diseases July 2021 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended dated July 12, 2021 File No. 333-256510
Slide 2: Forward-looking statements
This presentation contains forward-looking statements regarding future events and the future results of HCW Biologics Inc. (the “Company”) that are based on current expectations, estimates, forecasts, and projections about the industry in which the Company operates and the beliefs and assumptions of
Slide 3: Offering Summary
Issuer: HCW Biologics Inc. Exchange / Ticker: NASDAQ Global Market / HCWB Offering Type: Underwritten Initial Public Offering Securities Issued: Common Stock Gross Offering Proceeds: ~$50,000,000 Over-Allotment: 15% Estimated Offering Price Range: $8.00 to $10.00 per share of common stock Pre-Money
Slide 4: Novel Immunotherapeutics for Cancer and Other Aging-Associated Diseases
Novel Immunotherapeutics for Cancer and Other Aging-Associated Diseases Immunotherapeutics company in the emerging field of inflammaging Our gateway indication is oncology: AML, pancreatic, and solid tumors Many recent biotech IPOs have some similarities, but none with immunotherapeutic that has mul
Slide 5: HCW Product Pipeline
HCW Product Pipeline Program Product Indication Discovery IND-Enabling Phase 1 Phase 2 Phase 3 Oncology HCW9218 Pancreatic Cancer Other Solid Tumors Inflammaging Pulmonary Fibrosis HCW9302 Alopecia Areata
Slide 6: TOBI Platform Technology
TOBITM Platform Technology “Tissue FactOr-Based FusIon” Internally-developed, versatile scaffold can be utilized to generate designer, novel multi-functional fusion molecules. Scalable and reproducible for large-scale cGMP manufacturing. Drug product available to support clinical trials. Multiple pr
Slide 7: HCW Biologics' Immunotherapeutic Approach
HCW Biologics’ Immunotherapeutic Approach Two Primary Pathways Senescent cells and SASP factors Persistent activation of inflammasomes Deactivation of Inflammasomes Chronic Inflammation HCW9218 Senescent Cell Clearance & SASP Neutralization HCW9302 Central Nervous System Diseases Autoimmune Diseases
Slide 8: Potential for HCW9218 + Chemotherapy as a Treatment for Cancer
B16F10 N = 8-10 mice/group. Tumor Volume Reduction in Melanoma Day 0 4 8 10 2 6 HCW9218 (3 mg/kg) + TA99 (200µg) 12 DTX (10 mg/kg) Assess Tumor Growth Cells from Melanoma Tumor Overlay HCW9218+TA99 Saline Senescent Tumor Cells Saline Saline HCW9218+TA99 HCW9218+TA99 Potential* for HCW9218 + Chemothe
Slide 9: Potential for HCW9302 as a Treatment for Atherosclerosis
Potential* for HCW9302 as a Treatment for Atherosclerosis ** Week 0 4 8 10 2 Blood Collection 6 14 Sacrificed S.C. Injection 12 High Fat Diet Atherosclerotic Model: ApoE-/- and High Fat Diet. HFD HFD + HCW9302 * P<0.05 * HFD HFD+ HCW9302 PLAQUE * HFD HFD+ HCW9302 GLUCOSE * HFD HFD+ HCW9302 INSULIN R
Slide 10: Experienced Team with Success in Drug Discovery and Development
Experienced Team with Success in Drug Discovery and Development Hing C. Wong, PhD – Founder and CEO Former founder and CEO of Altor Bioscience, renamed ImmunityBio At Altor, developed ALT-803, an IL-15 superagonist complex (now named ANKTIVA) ANKTIVA received FDA Fast Track approval (2017) and Break
Slide 11: Recent IPOs
Recent IPOs Company Stage Gateway Indications Expanded Indications Approach Area Clinical Stage Oncology Fibrotic Diseases Diabetes Type 2 Autoimmune TGF-β SASP Neutralization Inflammasome Deactivation Immunotherapeutic ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü
Slide 12: Thank You!
Thank You! Rebecca Byam, MBA, CPABryan Kobel Chief Financial OfficerManaging Director HCW Biologics Inc.EF Hutton, division of Benchmark Investments, LLC (917) 885-1264(646) 286-1962 rebeccabyam@hcwbiologics.combkobel@efhuttongroup.com